



## Correction to: The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial

Sabashini K. Ramchand<sup>1</sup> · Joy N. Tsai<sup>1</sup> · Hang Lee<sup>2</sup> · Grace Sassana-Khadka<sup>1</sup> · Mackenzie Jordan<sup>1</sup> · Savannah Ryan<sup>1</sup> · Benjamin Z. Leder<sup>1</sup>

Published online: 9 November 2023

© International Osteoporosis Foundation and Bone Health and Osteoporosis Foundation 2023

### Correction to: Osteoporosis International

<https://doi.org/10.1007/s00198-023-06932-2>

In this article the ‘Co-first authorship’ note was missing, and should have read that Sabashini K. Ramchand and Joy N. Tsai are equal first authors. The original article has been corrected.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

The original article can be found online at <https://doi.org/10.1007/s00198-023-06932-2>.

---

✉ Sabashini K. Ramchand  
sramchand@mgh.harvard.edu

<sup>1</sup> Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA, USA

<sup>2</sup> Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA